Last reviewed · How we verify

intrathecal chemotherapy — Competitive Intelligence Brief

intrathecal chemotherapy (intrathecal chemotherapy) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Chemotherapy administration route (intrathecal). Area: Oncology.

marketed Chemotherapy administration route (intrathecal) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

intrathecal chemotherapy (intrathecal chemotherapy) — Princess Maxima Center for Pediatric Oncology. Intrathecal chemotherapy delivers chemotherapeutic agents directly into the cerebrospinal fluid to treat central nervous system malignancies and prevent leptomeningeal disease.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
intrathecal chemotherapy TARGET intrathecal chemotherapy Princess Maxima Center for Pediatric Oncology marketed Chemotherapy administration route (intrathecal)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Chemotherapy administration route (intrathecal) class)

  1. Princess Maxima Center for Pediatric Oncology · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). intrathecal chemotherapy — Competitive Intelligence Brief. https://druglandscape.com/ci/intrathecal-chemotherapy. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: